Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 35

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 35
---
 the Company’s executive officers or directors are U.S. citizens or residents; (2) more than 50% of
its assets are located in the United States; or (3) its business is administered principally in the United States.

The Company has taken advantage
of certain reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein may be different
than the information you receive from other public companies in which you hold equity securities.

In connection with the DiamiR
Merger, the Company will transfer by way of continuation to and domesticate as a Delaware corporation and it is anticipated that the Combined
Company will not be considered a foreign private issuer.

Notes on Prospectus Presentation

Numerical figures included
in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not
be arithmetic aggregations of the figures that precede them. Certain market data and other statistical information contained in this prospectus
is based on information from independent industry organizations, publications, surveys and forecasts. Some market data and statistical
information contained in this prospectus are also based on management’s estimates and calculations, which are derived from our review
and interpretation of the independent sources listed above, our internal research and our knowledge of pharmaceutical industry. While
we believe such information is reliable, we have not independently verified any third-party information and our internal data has not
been verified by any independent source.

Accordingly, actual events
or circumstances may differ materially from events and circumstances that are assumed in this information and you are cautioned not to
give undue weight to such data.

Company Corporate Information

The Company’s principal
executive office is located at 17 Hanover Square, London W1S 1BN, United Kingdom. Its telephone number is +44 20 80929299.

The Company’s website
is www.aptorumgroup.com. The information on our website is not part of this prospectus.

<div align='center'>14</div>

The Offering

| Issuer:                                                    |     | Aptorum Group Limited                                                                                                                                                                                                                                                                |
| Class A Ordinary Shares being offered                      |     | Up to ‌[   ] Class A Ordinary Shares                                                                                                                                                                                                                                                 |
| Price per share                                            |     | The assumed public offering price is $___ per share, which represents                                                                                                                                                                                                                
 the closing price of our Class A Ordinary Shares as reported on Nasdaq Capital Market on [    ], 2025. The final                                                                                                                                                                     
 offering price will be determined